Know Cancer

forgot password

Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway Disease

18 Years
Open (Enrolling)
Squamous Cell Lung Cancer, Lung Cancer, Pulmonary Disease

Thank you

Trial Information

Pilot Study To Evaluate Optical Frequency Domain Imaging For Diagnosis Of Central Airway Disease

This study will evaluate the potential of a new imaging device, the Optical Frequency Domain
Imaging (OFDI) for imaging pulmonary malignancy in the central airways.

The prevalence and high mortality rate associated with Lung Squamous Cell Carcinoma and the
lack of any widely accepted screening and surveillance tools, highlights the need for new
imaging paradigms that will ultimately lead to a reduction in patient mortality.

Bronchial carcinoma in-situ will progress to invasive cancer in over 40% of individuals, and
although the progression occurs over a long period of time, the majority of carcinomas are
detected in the later stages of disease development, offering patients only a very slim
chance of cure. Although, significant effort in the development of screening paradigms for
the detection of lung cancer in the central airway has been made, to date there is still no
widely accepted and validated approach. Optical Frequency Domain Imaging (OFDI) is a recent
derivative of optical coherence tomography (OCT). As in OCT, OFDI is an interferometric
ranging technique that can roughly be considered to be an optical analogue of ultrasound
imaging and can provide tomographic images of tissue at resolutions comparable with
architectural histology. The long term goal of this study is to use OFDI to screen the
airways with the hope of detecting Squamous Cell Carcinoma at an earlier more curable stage.

Standard of care bronchoscopy preparation and procedures to be followed, with moderate
sedation, pulse oximetry and blood pressure monitoring as per department protocol. A
combination of currently approved bronchoscopy techniques including stand white light
bronchoscopy, autofluorescence bronchoscopy, and narrow band imaging will be used to assess
the airways.

Bronchial regions of interest (ROI's)suspected to be premalignant or malignant, identified
during the bronchoscopy procedure, will be imaged using the OFDI system and catheter before
biopsy is done. It is anticipated to obtain a minimum of 3 OFDI-biopsy correlated pairs from
each study participant. An additional OFDI image and biopsy will be obtained from region's
of normal interest (ROI's). It is expected that the experimental procedure will add less
than 10 minutes to the total length of the bronchoscopy procedure, but a stopping rule will
be instituted to ensure that the experimental procedure does not exceed 20 minutes.

Inclusion Criteria:

- Patients undergoing bronchoscopy for known or suspected pulmonary malignancy in the
central airways

- Patients must be over the age of 18

- Patient must be able to give informed consent

- Women with child bearing potential must have a negative pregnancy test within seven
days prior to the procedure

Exclusion Criteria:

- PaO2 less than 80 on FiO2 greater 70%

- Systolic blood pressure less than 90

- Active bronchospasm

- INR greater than 2.0 (INR: International Normalized Ratio)

- Recent myocardial infarction within last two weeks

- Active cardiac chest pain

- Significant untreated sleep apnea

- FEV1 less than 30% of predicted (FEV1: forced expiratory volume in 1 second)

- Worsening hypercarbia with PaCO2 greater than 55

- In active respiratory failure (unless endotracheal intubation is performed first to
stabilize the airway)

Type of Study:


Study Design:

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic

Outcome Measure:

Obtain biopsy correlated OFDI images with the purpose of establishing OFDI image criteria for discrimination of tissue types.

Outcome Time Frame:

One time Bronchoscopy

Safety Issue:


Principal Investigator

Anthony W Bonhert, M.D.

Investigator Role:

Principal Investigator

Investigator Affiliation:

Lahey Clinic, Inc.


United States: Food and Drug Administration

Study ID:




Start Date:

March 2008

Completion Date:

March 2014

Related Keywords:

  • Squamous Cell Lung Cancer
  • Lung Cancer
  • Pulmonary Disease
  • Lung Cancer
  • Squamous Cell Lung Cancer
  • Bronchial carcinoma in situ
  • Central Airway Diseases
  • Lung Diseases
  • Respiration Disorders
  • Lung Neoplasms



Lahey Clinic, Inc.Burlington, Massachusetts  01805